Страна: Южна Африка
Език: английски
Източник: South African Health Products Regulatory Authority (SAHPRA)
Adcock
BURINEX® K SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form) BURINEX ® K Tablets COMPOSITION: Each tablet contains: Bumetanide 0,5 mg and Potassium Chloride 573 mg (in a slow release wax core). PHARMACOLOGICAL CLASSIFICATION: A 18.1 Diuretics PHARMACOLOGICAL ACTION: BURINEX ® K combines the very high potent high-ceiling diuretic bumetanide, with a slow release potassium chloride supplement. Bumetanide has a rapid onset and a short duration of action. As with most diuretics, long-term therapy may be associated with potassium depletion. In-vitro studies suggest that the potassium supplement in BURINEX ® K may help to maintain normal levels of potassium, especially in those patients whose dietary intake of potassium is inadequate. The formulation of BURINEX ® K presents the following advantages. The diuretic is coated round the tablet, from which it is rapidly released. The diuretic and saliuretic effect begins within 30 minutes after oral administration, peaks at 1- 2 hours and is largely complete within 3 hours. In-vitro studies suggest that, in contrast, the potassium chloride which is included in an inert wax core, is released only slowly over a period of 6 hours after oral ingestion. This slow release minimises the risk of gastro-intestinal intolerance as well as that of ulceration and stenosis resulting from localised high concentrations of potassium salts in the small bowel. (For further pharmacological and clinical data on BURINEX ® itself, see BURINEX ® Data Sheet). This medicine contains potassium chloride. It has not been proven that this dosage will necessarily prevent a significant potassium loss or correct an existing deficiency of potassium. INDICATIONS: BURINEX ® K is indicated for the treatment of all forms of oedema, particularly where suppl Прочетете целия документ